Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Percutaneous Coronary Intervention
95%
Transcatheter Aortic Valve Replacement
93%
Acute Coronary Syndrome
52%
Myocardial Infarction
50%
Heparin
46%
Acute Myocardial Infarction
45%
Abciximab
37%
Aspirin
35%
Drug-eluting Stent
35%
Clinical Outcomes
35%
Glycoprotein IIb-IIIa
33%
Platelets
33%
Surgical Aortic Valve Replacement
32%
Clinical High Risk
31%
All-cause Mortality
27%
Stable Angina
25%
Ischemic Events
25%
Confidence Interval
25%
Platelet Aggregation
25%
Platelet Glycoproteins
24%
Glycoprotein IIb/IIIa Inhibitors
24%
Revascularization
23%
High Risk
23%
Eptifibatide
20%
Angioplasty
20%
Placebo
20%
Platelet Inhibition
19%
Transcatheter Heart Valve
19%
Clopidogrel
19%
Non-ST-segment Elevation Acute Coronary Syndrome (NSTE-ACS)
18%
Thrombolysis
18%
Severe Aortic Stenosis
17%
CoreValve
17%
ST-elevation Myocardial Infarction (STEMI)
17%
Bivalirudin
16%
Transcatheter
16%
Coronary Angioplasty
16%
Bleeding
15%
Bolus
15%
Transcatheter Aortic Valve Implantation
14%
Transcatheter Edge-to-edge Repair
14%
Coronary Artery Disease
13%
Pharmacodynamics
13%
Thrombolytic Therapy
12%
Hazard Ratio
12%
Self-expanding
12%
Meta-analysis
12%
Cardiogenic Shock
12%
Randomized Clinical Trial
12%
Odds Ratio
11%
Medicine and Dentistry
Percutaneous Aortic Valve Replacement
100%
Percutaneous Coronary Intervention
81%
Acute Coronary Syndrome
49%
Myocardial Infarction
47%
Aortic Valve Replacement
37%
Drug-Eluting Stent
34%
Platelet
34%
Apoplexy
29%
Revascularization
29%
Aortic Stenosis
29%
All Cause Mortality
28%
Acute Heart Infarction
27%
Coronary Artery Disease
24%
Abciximab
23%
Heparin
23%
Aortic Valve
22%
Transluminal Coronary Angioplasty
21%
ST Elevation
21%
Acetylsalicylic Acid
18%
Meta-Analysis
17%
Congestive Heart Failure
17%
Angioplasty
16%
Unstable Angina Pectoris
16%
Hazard Ratio
16%
Platelet Glycoprotein IIb/IIIa
16%
Mitral Insufficiency
15%
Fibrinogen Receptor
15%
Aortic Valve Prosthesis
15%
Placebo
15%
Clinical Trial
14%
Surgical Risk
14%
Blood Clot Lysis
14%
Odds Ratio
14%
Randomized Clinical Trials
13%
Bleeding
13%
Antiplatelet
13%
Thrombosis
13%
Infarction
12%
Cardiogenic Shock
12%
Target Lesion Revascularization
12%
Thrombocyte Aggregation
12%
Cardiovascular System
12%
Tricuspid Insufficiency
11%
Coronary Artery Bypass Graft
11%
Coronary Angiography
11%
In-Stent Restenosis
10%
Fibrinolytic Therapy
10%
Brachytherapy
10%
Eptifibatide
9%
Heart Transplantation
9%
Pharmacology, Toxicology and Pharmaceutical Science
Heart Infarction
63%
Heparin
55%
Acute Coronary Syndrome
55%
Fibrinogen Receptor
51%
Abciximab
39%
Acute Heart Infarction
37%
Acetylsalicylic Acid
35%
Coronary Artery Disease
28%
Eptifibatide
25%
Placebo
25%
All Cause Mortality
24%
Bleeding
22%
Unstable Angina Pectoris
22%
Infarction
18%
Clopidogrel
18%
Antiplatelet
17%
Clinical Trial
17%
Cerebrovascular Accident
17%
Pharmacodynamics
16%
Fibrinolytic Agent
16%
Bivalirudin
16%
Receptor
15%
Alteplase
13%
Congestive Heart Failure
12%
Combination Therapy
11%
Aortic Stenosis
11%
Anticoagulant Agent
10%
Tissue Plasminogen Activator
10%
Adenosine Diphosphate
10%
Enoxaparin
9%
Ischemia
9%
Thrombosis
9%
Randomized Controlled Trial
9%
Non ST Segment Elevation Myocardial Infarction
8%
ST Segment Elevation Myocardial Infarction
8%
Pharmacokinetic
8%
Thrombin
7%
Diabetes Mellitus
7%
Cardiogenic Shock
7%
Heart Muscle Ischemia
7%
Streptokinase
7%
Cardiovascular Disease
6%
Fibrinogen Receptor Antagonist
6%
Thrombocytopenia
6%
Thrombus
6%
Normal Human
6%
P-Selectin
6%
In-Stent Restenosis
6%
Stable Angina Pectoris
6%
Restenosis
6%